Avita Medical (RCEL) announced the appointment of David O’Toole as its new CFO, effective June 15. O’Toole is an accomplished financial executive with more than 30 years of experience in global corporate finance, capital markets, and accounting across biotech and life sciences companies. He has a demonstrated track record of developing and executing successful growth strategies in a number of public companies. O’Toole will play a critical role in executing the company’s strategic growth initiatives and in leading the financial organization. O’Toole most recently served as CFO of Opiant Pharmaceuticals (OPNT).
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on RCEL:
- AVITA Medical Announces FDA Approval of RECELL for Skin Repigmentation in Vitiligo Patients
- AVITA Medical Announces Appointment of David O’Toole as Chief Financial Officer
- AVITA Medical Announces FDA Approval of RECELL for Treatment of Full-Thickness Skin Defects
- AVITA Medical to Host Investor Webinar Briefing
- AVITA Medical Reports First Quarter Financial Results and Affirms Full Year Guidance